There is some evidence to suggest the use of ACE inhibitors and ARBs as first-line agents in the obesity-linked primary hypertension population; in adults, these agents appear to reduce the incidence of new-onset diabetes and may increase insulin sensitivity [84]. This evidence concerns the gene ACE and obesity disorder.